AMEBAGONE INC
Medtech · Private
Dictyostelid cell-based biocontrol therapeutic for bacterial keratitis treatment
- Grants
- $3.5M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Biological treatment of bacterial keratitis | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Biological treatment of bacterial keratitis | $224,999 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II: Natural biocides for treating bacterial pathogens in pome fruits and vegetable crops | $902,590 | |
| Federal grant | Department of Health and Human Services · Phase II · Biological Treatment of Bacterial Keratitis | $171,203 | |
| Federal grant | Department of Health and Human Services · Phase II · Biological Treatment of Bacterial Keratitis | $532,480 | |
| Federal grant | Department of Agriculture · Combatting Potato Soft Rot With Free-living Phagocytes | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Biological Treatment of Bacterial Keratitis | $721,237 | |
| Federal grant | Department of Agriculture · Amebagone, Inc Is Developing A Novel Microbial Pesticide For The Prevention Of Soft Rot In Potato Tubers. Each Year, An Estimated 15-30% Of The U.S. Potato Crop Is Lost To Soft Rot, Representing A Market Loss Of $0.57B-$1.13B. There Is Currently No Effective Treatment Available For This Disease. Our Solution Is A Biological Treatment That Uses The Predatory Power Of Dictyostelids (dicty For Short) Instead Of Harsh Chemicals. Dicty Are Microscopic Organisms That Live In The Soil Where They Feed S | $646,368 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2247 | ARRHYTHMIA DYNAMICS, LLC | — | — |
| 2248 | SIT SENSE, INC | — | — |
| 2249 | AQUILO SPORTS, LLC | — | — |
| 2250 | AMEBAGONE INC | — | — |
| 2251 | COLORADO PHOTOPOLYMER SOLUTIONS, LLC | — | — |
| 2252 | ZINN LABS, INC. | — | — |
| 2253 | NEUROTYPE INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.